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ABSTRACT
Aim: To investigate effects on men’s health and well-
being of higher prostate cancer (PCa) investigation and
treatment levels in similar populations.
Participants: PCa survivors in Ireland where the
Republic of Ireland (RoI) has a 50% higher PCa
incidence than Northern Ireland (NI).
Method: A cross-sectional postal questionnaire was
sent to PCa survivors 2–18 years post-treatment,
seeking information about current physical effects of
treatment, health-related quality of life (HRQoL; EORTC
QLQ-C30; EQ-5D-5L) and psychological well-being (21
question version of the Depression, Anxiety and Stress
Scale, DASS-21). Outcomes in RoI and NI survivors
were compared, stratifying into ‘late disease’ (stage III/
IV and any Gleason grade (GG) at diagnosis) and ‘early
disease’ (stage I/II and GG 2–7). Responses were
weighted by age, jurisdiction and time since diagnosis.
Between-country differences were investigated using
multivariate logistic and linear regression.
Results: 3348 men responded (RoI n=2567; NI
n=781; reflecting population sizes, response rate 54%).
RoI responders were younger; less often had
comorbidities (45% vs 38%); were more likely to
present asymptomatically (66%; 41%) or with early
disease (56%; 35%); and less often currently used
androgen deprivation therapy (ADT; 2%; 28%). Current
prevalence of incontinence (16%) and impotence (56%
early disease, 67% late disease) did not differ between
RoI and NI. In early disease, only current bowel
problems (RoI 12%; NI 21%) differed significantly in
multivariate analysis. In late disease, NI men reported
significantly higher levels of gynaecomastia (23% vs
9%) and hot flashes(41% vs 19%), but when ADT
users were analysed separately, differences
disappeared. For HRQoL, in multivariate analysis, only
pain (early disease: RoI 11.1, NI 19.4) and financial
difficulties (late disease: RoI 10.4, NI 7.9) differed
Strengths and limitations of this study
▪ This large study used the same approaches in
both geographical areas for patient definition,
recruitment, data collection and analysis with
validated instruments used to assess patient-
reported outcomes. Also, men were categorised
for analysis by stage and grade of disease to
help compensate for differences in the patient
profile of the two populations.
▪ High-quality population-based cancer registries
provided the basis for sampling allowing popula-
tion representativeness to be assessed and pro-
portions weighted to the entire survivor
population.
▪ Lack of information on baseline health at diagno-
sis and symptoms at diagnosis are potential limi-
tation and we acknowledge this could be more
of a problem with the older Northern Ireland (NI)
population and for men diagnosed longer ago;
however, health and health-related quality of life
(HRQoL) effects were measures as reported
currently.
▪ While the categorisation into early and late
disease was loosely based on D’Amico criteria,
PSA levels at diagnosis were not systematically
available and Gleason scores were recorded in
the registries as a categorical variable, with a
cut-off at 7.
▪ We did not collect data from men in the popula-
tion without prostate cancer (ie, normative data),
so we cannot be sure that the background preva-
lence of physical symptoms, such as ED, or
levels of HRQoL or psychological well-being
does not differ between NI and Republic of
Ireland. (A normative study is, however,
underway.)
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significantly between countries. There were no significant between-
country differences in DASS-21 or index ED-5D-5L score.
Conclusions: Treatment side effects were commonly reported and
increased PCa detection in RoI has left more men with these side
effects. We recommended that men be offered a PSA test only after
informed discussion.
INTRODUCTION
Age-standardised prostate cancer (PCa) incidence has
increased over the past two decades associated with
increased use of PSA testing,1 so that now in many coun-
tries it is the most common cancer among males.2 The
debate about the value of PSA testing for the early
detection of PCa continues. While a simple blood test
and the prospect of earlier cancer diagnosis are appeal-
ing, poor speciﬁcity leads to overdiagnosis of clinically
insigniﬁcant cancers.3 To be considered effective,
screening must reduce overall and disease-speciﬁc mor-
tality and morbidity and not just detect more disease.
Only one large long-term randomised controlled trial
has identiﬁed a signiﬁcant reduction in deaths asso-
ciated with Prostate Speciﬁc Antigen (PSA) ‘screening’,
but this was accompanied by a high level of overdiagno-
sis and associated treatment.4 Despite this, marked inter-
national variations in PCa incidence rates point to
widespread use of PSA testing for unsuspected PCa2 and
recent calls to offer men in their 40 s access to the PSA
test is likely to further increase numbers diagnosed.5 In
the light of this, and in order to inform the PSA debate,
it would be of value to determine whether more investi-
gation and treatment improves men’s self-reported
health outcomes, especially in the long term.
Circumstances exist in Ireland where different inten-
sities of PSA testing and subsequent biopsy between its
two jurisdictions, Republic of Ireland (RoI) and
Northern Ireland (NI), exist in populations which are
similar in lifestyle and ethnic and genetic makeup.6
Both jurisdictions have high-quality population-based
cancer registries which have tracked PCa incidence since
the early 1990s.7 8 The RoI has a complex mixed
public–private healthcare system and rates of PSA testing
in men aged 50 and older rose by 23% per annum
between 1993 and 2005.6 In 2006, the National Cancer
Forum recommended against the introduction of PSA
screening; however, high levels of testing persisted.9 In
contrast, NI has a predominantly publicly funded health-
care system similar to the NHS and has encouraged fol-
lowing the National Screening Committee’s advice in
2002 and the National Institute for Health and Care
Excellence (NICE) guidelines (2008) aimed at limiting
the use of PSA testing in primary care.10 11 Nevertheless,
there is evidence of screening for PCa in the NI popula-
tion,12 although at markedly lower levels (annual per-
centage change 1993 to 2003=+9.7%) than in RoI.6
Consequently, since 1994, when PCa incidence rates
were similar, the age-standardised incidence rate has
risen by 222% in RoI compared with 161% in NI. These
unique circumstances allow us to investigate the effect of
more intense investigation and treatment of PCa on
men’s health and well-being.
METHODS
This work was undertaken as part of the PiCTure
(Prostate Cancer Treatment, your experience) study, which
was conducted in RoI and NI, the methods of which
have been described previously13 and in short are
described below.
Patient involvement
Patients were involved in study steering group, piloting
of questionnaire and interpretation of results.
Participants/patients
Following ethical approvals, a population-based sample
of all men diagnosed with invasive PCa (International
Classiﬁcation of Diseases (ICD10 C61) between 1
January 1995 and 31 March 2010, and alive in
November 2011, was selected from the two population-
based cancer registries (n=22 823). From this, a country
and time (with approximately the same numbers under
and over 5 years since diagnosis) stratiﬁed random
sample of 12 322 men was selected. This was required as
there were fewer survivors diagnosed in the earlier years
for two reasons: one, the levels of PCa diagnosed were
lower; and second, since at least 50% of PCa cases are
over 70 when diagnosed, so mortality would have
reduced numbers.
Patients’ general practitioners/healthcare profes-
sionals were contacted to screen men for eligibility to
participate in the study. Men were eligible if they were
(1) alive, (2) aware of their PCa diagnosis, (3) well
enough to receive and complete a questionnaire (in par-
ticular, had no cognitive impairment), (4) able to under-
stand English and (5) resident in RoI or NI. Following
this process, 6559 PCa survivors were deemed eligible to
be sent a questionnaire. Questionnaires were posted in
2012. Non-responders received up to two written
reminders.
Outcome measures
The primary outcome variables for this analysis were
determined by questionnaire and were
1. PCa-related physical symptoms ‘currently’ experi-
enced (ie, present at time of questionnaire comple-
tion; erectile dysfunction (ED), urinary incontinence,
bowel problems, loss of libido, gynaecomastia and
hot ﬂashes/sweats).
2. Health utility on the day of questionnaire completion,
measured by the 5 level health status measure
EQ-5D-5L which comprises ﬁve dimensions: mobility,
self-care, usual activities, pain/discomfort and
anxiety/depression. Each dimension has ﬁve possible
levels of response: no problems, slight, moderate, severe or
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unable to undertake the particular action. The EQ-5D-5L
health states were converted to EQ-5D-3L states and
UK valuations applied to provide a single index value
of up to 1 (since there are no valuations speciﬁcally
for Ireland and NI is part of the UK);14 15 higher
values indicate better/more health utility.
3. Health-related quality of life (HRQoL) in the past
week measured using the European Organisation for
Research and Treatment of Cancer - Quality of Life
Questionnaire (EORTC QLQ)-C3016 a general
cancer questionnaire comprising a global health
score (GHS), ﬁve functional subscales (measuring
physical, role, emotional, cognitive and social func-
tioning) and nine general cancer symptom subscales
(assessing fatigue, nausea/vomiting, pain, dyspnoea,
sleep disturbance, loss of appetite, constipation, diar-
rhoea and ﬁnancial difﬁculties). Response options
range from 1 (not at all) to 4 (very much), except
for the two questions comprising the GHS, responses
to which ranged from 1 (very poor) to 7 (excellent).
Scores on each subscale were transformed to 0–100
as recommended, with higher scores indicating
better HRQoL, higher functioning or worse
symptoms).16
4. Psychological well-being during the past week, assessed
by the 21 question version of the Depression, Anxiety
and Stress Scale (DASS-21)17 which contains three
subscales which measure depression, anxiety and (di)
stress. Each subscale is based on seven questions with
responses scored from 0 (did not apply) to 3 (applied
to me very much, or most of the time). A summary
score for each subscale was generated by doubling the
sum of the individual responses. Possible scores on
each scale range from 0 to 42, with higher scores indi-
cating higher levels of depression, anxiety or stress.
Explanatory variables
Men were asked to report all treatments received, by
answering yes/no to a list of treatments (radical prosta-
tectomy (RP), external beam radiotherapy (EBRT),
androgen deprivation therapy (ADT), active surveillance
(AS), watchful waiting (WW) and brachytherapy (BT)).
The questionnaire also requested information on socio-
demographic characteristics, method of diagnosis
(‘symptomatic clinically detected’ or ‘asymptomatic PSA
detected’)13 and health at diagnosis, in particular
urinary (increase in frequency, pain while urinating,
blood in urine) or sexual (impotence/erectile dysfunc-
tion) symptoms (yes/no) and presence of comorbidities
(which men were invited to select from a list comprising
heart or lung disease, stroke, diabetes, high blood pres-
sure, diverticular disease, bowel problems (eg, constipa-
tion/diarrhoea), other cancer, depression or other).
Date of diagnosis, stage at diagnosis (tumour-lymph
node-metastasis classiﬁcation) and Gleason grade (GG)
for all men who were sent questionnaires were extracted
from the cancer registries. GG is collected by the RoI
cancer registry National Cancer Registry Ireland,
(NCRI) as a categorical variable (low (GG 2–4),
medium (GG 5–7) or high grade (GG 8–10), so these
categories were used in analysis. Supplementary staging
information was abstracted from medical records for NI
respondents in early years when staging levels in the
N. Ireland Cancer Registry (NICR) were low.
Statistical analysis
The goal of the analysis was to compare health and well-
being between men from RoI and NI. However, the
characteristics of the populations of patients with PCa
and therefore the populations of survivors and respon-
dents differed between RoI and NI, notably in the pro-
portions of early and late disease. To overcome this, and
since disease extent at diagnosis is likely to be an import-
ant determinant of health and well-being, analyses
adjusted for sociodemographic and clinical characteristics
were undertaken and outcomes were analysed separately
for two main categories: ‘late disease’ deﬁned as stage III
or IV and any GG at diagnosis and ‘early disease’ deﬁned
as stage I/II and GG 2–7 at diagnosis. A third group,
‘other’, which included those without stage or grade or
with early stage and high grade, was also created and
summary ﬁndings are reported for completeness.
Survey responses were weighted by age, country and
time since diagnosis to compensate for higher non-
response in certain survivor subgroups13 and increase
representativeness of the results to the entire PCa sur-
vivor population.
Differences in proportions of patient characteristics,
symptom and functional scores and DASS-21 subscales
between survivors from NI and RoI were tested using
z-tests and χ2 tests for early and late disease separately.
Multivariate regression models (logistic for physical symp-
toms and linear for health utility, HRQoL and psycho-
logical well-being) were developed using a staged
approach. The ﬁrst model adjusted for age at question-
naire completion, number of comorbidities at diagnosis,
time since diagnosis and method of diagnosis (model 1).
The second model (model 2) then added treatments (RP,
EBRT, BT, ADT) since treatment usage differs between
RoI and NI. Records with missing treatment or method of
diagnosis were dropped from all models (n=60).
Signiﬁcance was at the 5% level with the Bonferroni
correction applied to compensate for multiple compari-
sons (see table footnotes for details of signiﬁcance levels
for each analysis).
RESULTS
In total, 3348 men responded, providing a 54% overall
response rate after adjustment for men who were discov-
ered to be ineligible following questionnaire dispatch.
Seventy per cent of responders were from RoI (n=2567)
and 30% (n=781) from NI, reﬂecting the different
country population numbers.
Almost half of the respondents (48%) were surveyed
2–4.9 years postdiagnosis, 32% were surveyed 5–9.9 years
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and 20% were surveyed ≥10 years after diagnosis.
Respondents’ average age at diagnosis was 649 years
(SD 76). Men from RoI were younger, more often
reported asymptomatic PSA detection of their cancer
and more often presented without urinary symptoms or
without comorbidities compared with respondents from
NI (all p<0.001). Respondents from NI more often
reported having ADT or EBRT, and less often having RP
or BT compared with respondents from RoI (table 1).
Overall, 51% of respondents (n=1700) were classiﬁed
as early stage disease at diagnosis. Early disease survivors
accounted for 56% of RoI respondents (n=1431) and
35% of NI respondents (n=269). Overall, 21% of respon-
dents had late disease (n=689), and this comprised 36%
of NI responders (n=282) and 16% of RoI responders
(n=407). This left 959 (29% overall) in the ‘other’
group, representing an almost identical percentage of
respondents from RoI (28%) and NI (29%).
Men with early disease at diagnosis
There were no differences between early disease patients
in NI and RoI in terms of age or comorbidities at diag-
nosis, current age, marital status, or (not shown) living
alone and family history. Responders with early disease
from RoI were more likely to have been diagnosed 5–
10 years previously (46% vs 35%); more often asymptom-
atic PSA-detected; more often treated with RP; less often
treated with EBRT, ADT or AS/WW and more likely to
report no symptoms at diagnosis. Men from NI were
more often diagnosed in the previous 2–5 years and
more likely to report increased frequency of urination at
diagnosis (all p<0.001; table 1).
There were no signiﬁcant differences between early
disease patients from NI and RoI in reported ‘current’
PCa-related physical symptoms for urinary incontinence
(overall weighted percentage, 15%), libido loss (42%),
erectile dysfunction (56%), breast changes (5%), hot
ﬂashes (9%) or reporting at least one physical symptom
(76%). Signiﬁcant differences existed in univariate ana-
lysis for bowel problems and fatigue, both of which were
more common in NI (table 2). In multivariate analysis
adjusting for age, comorbidities, time since diagnosis
and method of diagnosis (model 1), these differences
remained signiﬁcant. When treatment was added
(model 2), only bowel problems remained signiﬁcant
(OR 1.8, 95% CI 1.26 to 2.56, p=0.001; table 2).
For health utility and HRQoL, better outcomes among
men from RoI than NI were suggested in univariate ana-
lysis by higher scores for EQ-5D-5L, QLQ-C30 physical
and role functioning and lower scores for QLQ-C30
fatigue, pain dyspnoea and insomnia. Apart from phys-
ical functioning and insomnia, these differences
remained signiﬁcant in multivariate model 1; however,
only pain (which was higher for men from NI)
remained signiﬁcant when treatment was added (model
2; RoI 11.1, NI 19.4, coefﬁcient 5.829, CI 2.349 to 9.308,
p=0.001; table 2). In terms of psychological well-being,
there were no signiﬁcant differences between RoI and
NI for depression, anxiety or distress scores in univariate
or multivariate analysis (table 3).
Men with late disease at diagnosis
There were no differences in current age, time since
diagnosis, family history of PCa or speciﬁc comorbidities
Table 1 Characteristics of men and treatment received by disease category and jurisdiction (weighted proportions)
Early disease* Late disease†
All respondents
(includes those
classified as ‘other’)
RoI NI RoI NI RoI NI
Weighted numbers 1431 269 407 282 2567 781
Age at diagnosis >70 years 27.6% 32.9% 30.3% 38.4% 32.4%‡ 40%‡
Age at diagnosis <60 years 25.2% 21.8% 25.6%‡ 15%‡ 22.8%‡ 17.4%‡
Symptomatic clinically detected 28.3%‡ 51.4%‡ 37.5‡ 59.0‡ 32.3%‡ 58.2%‡
Asymptomatic PSA detected 70.2%‡ 48.4%‡ 61.3%‡ 40.4%‡ 66.2%‡ 41.1%‡
No symptoms at diagnosis 38.3%‡ 24.2%‡ 35.8%‡ 23.8%‡ 36.7%‡ 23.0%‡
Urinating more frequently at diagnosis 45.9%‡ 64.3%‡ 45.0%‡ 58.3%‡ 47.5%‡ 62.7%‡
No comorbidities at diagnosis 45.4% 39.0% 51.2%‡ 34.9%‡ 45.2%‡ 38.0%‡
Radical prostatectomy 34.8%‡ 15.7%‡ 39.2% 10.5%‡ 30.9%* 13.9%‡
External beam radiotherapy 51.5%‡ 64.4%‡ 64.1%‡ 79.1%‡ 55.7%‡ 64.1%‡
Brachytherapy 7.4% 4.9% 3.2% 0% 6.6%‡ 1.8%‡
Androgen deprivation therapy (ever) 27.9%‡ 60.0%‡ 52.5%‡ 87.1%‡ 37.3%‡ 71.9%‡
Chemotherapy 1% 0.3% 3.8% 3.7% 2% 1.8%
Active surveillance/watchful waiting 5%‡ 10.2%‡ 1.3% 0.2% 4.7% 5.7%
No treatment 2.9% 1.8% 2.0% 0.0% 3.2% 2.5%
Results are weighted by country, age at diagnosis and time since diagnosis.
*Early=stage I/II Gleason grade 2–7.
†Late=stage III/IV any Gleason grade.
‡Significant difference at (notional p<0.05, p<0.001 with Bonferroni correction applied).
NI, Northern Ireland; RoI, Republic of Ireland.
4 Gavin AT, et al. BMJ Open 2016;6:e012952. doi:10.1136/bmjopen-2016-012952
Open Access
group.bmj.com on January 9, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
at diagnosis between RoI and NI men with late disease
(not shown). Responders with late disease from the RoI
more often were under age 60 at diagnosis and reported
no comorbidities at diagnosis. Men with late disease from
NI more often reported urinating more frequently at
diagnosis; they also more often presented symptomatic-
ally, were less often treated with RP and were more often
treated with EBRTor ADT (all p<0.001 table 1).
In terms of physical cancer-related symptoms in men
with late disease, there were no signiﬁcant differences for
ongoing urinary incontinence (overall weighted percent-
age 20%), erectile dysfunction (67%) or bowel problems
(17%) between men from NI and RoI. Loss of libido,
breast changes, hot ﬂashes and fatigue were signiﬁcantly
more frequently reported in men from NI. These differ-
ences remained after adjustment for age, comorbidities,
time since diagnosis and method of diagnosis (model 1),
but when treatment was added to the model (model 2)
only breast changes (OR 2.3, 95% CI 1.41 to 3.73) and
hot ﬂashes (OR 2.33, 95% CI 1.55 to 3.51) remained sig-
niﬁcant, although the ORs were attenuated (table 4).
For health utility, HRQoL and psychological well-
being, only QLQ-C30 ﬁnancial difﬁculties scores differed
signiﬁcantly in multivariate analyses (RoI 17.9 vs NI 10.4;
model 2: coefﬁcient=8.629, CI −12.770 to 4.488,
p<0.001; table 5).
‘Other’ group
Of the ‘other’ group (n=959), 300 had stage I/II high-
grade (8–10) disease, and the remainder had either
unknown stage (n=171) and/or unknown grade (n=372;
for 116, both were unknown). There were no signiﬁcant
differences between responders from NI and RoI for any
outcomes in the fully adjusted multivariate model
(model 2; see online supplementary table S1).
DISCUSSION
Using data from this large sample of PCa survivors of all
ages and those who had received all forms of treatment,
we compared men’s reported physical symptoms, psycho-
logical well-being, health utility and HRQoL between
two countries with different policies and practices in
relation to PCa detection. This unique set of circum-
stances—where clinicians in RoI undertake more PSA
testing of asymptomatic men in primary care and refer
more men to hospital for prostate biopsy, resulting in a
considerably higher incidence of PCa than in NI—has
resulted in differences between countries in the proﬁle
of PCa, in terms of the sociodemographic characteristics
of the men diagnosed, the distribution of disease stage
and grade, and patterns of treatment usage6 By examin-
ing patients with early and late disease separately, we are
able to compare patient-reported outcomes between two
similar populations with different levels of investigation
and treatment. We found that while survivors from RoI
were younger, with earlier disease and fewer comorbid-
ities than those from NI, patient-reported outcomes
were similar when stratiﬁed by disease extent at diagno-
sis; indeed, very few signiﬁcant differences were found
once adjustment had been made for patient character-
istics and treatment.
Table 2 Prostate cancer-related physical symptoms—early disease patients
Stage I/II—Gleason grade 2–7 Univariate model Multivariate model 1* Multivariate model 2†
Weighted
proportion
OR OR OR
Ongoing side
effects
(NI vs RoI) (NI vs RoI) (NI vs RoI)
RoI (%) NI (%) (RoI as baseline) (RoI as baseline) (RoI as baseline)
Urinary incontinence 14.3 17.8 1.26 1.12 1.43
(0.90 to 1.74) p=0.173 (0.81 to 1.56) p=0.485 (0.99 to 2.07) p=0.057
Loss of libido 41.3 48.0 1.27 1.30 1.20
(0.98 to 1.64) p=0.068 (1.00 to 1.69) p=0.046 (0.91 to 1.59) p=0.198
Erectile dysfunction 56.1 56.9 1.01 1.16 1.24
(0.78 to 1.30) p=0.950 (0.88 to 1.52) p=0.289 (0.92 to 1.68) p=0.163
Bowel problems 11.5 21.1 2.07‡ 1.87‡ 1.80‡
(1.49 to 2.89) p<0.001 (1.32 to 2.64) p<0.001 (1.26 to 2.56) p=0.001
Breast changes
(gynaecomastia)
4.6 7.9 1.78 1.63 0.93
(1.12 to 2.83) p=0.015 (1.02 to 2.59) p=0.042 (0.56 to 1.54) p=0.772
Hot flashes 8.4 10.9 1.30 1.15 0.70
(0.87 to 1.94) p=0.199 (0.76 to 1.74) p=0.503 (0.44 to 1.13) p=0.144
Fatigue 17.0 28.7 1.98‡ 1.76‡ 1.53
(1.47 to 2.66) p<0.001 (1.30 to 2.39) p<0.001 (1.12 to 2.10) p=0.008
Results are weighted by country, age at diagnosis and time since diagnosis.
*Logistic regression model adjusted for age at questionnaire completion, number of comorbidities at diagnosis, time since diagnosis and
method of diagnosis.
†Logistic regression model adjusted for the above plus prostatectomy, external beam radiotherapy, brachytherapy and hormone therapy
records with missing treatment or method of diagnosis dropped from all models (n=60). Significant difference at p<0.05 but with Bonferroni
correction applied.
‡Significant difference between countries.
NI, Northern Ireland; RoI, Republic of Ireland.
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Table 3 Patient-reported health utility, health-related quality of life and psychological well-being outcomes—early stage prostate cancer—RoI versus NI
Outcome and
instrument/subscale
Weighted
mean
Univariate model Multivariate model 1* Multivariate model 2†
NI vs RoI NI vs RoI NI vs RoI)
RoI NI Coefficient 95% CI p Value Coefficient 95% CI p Value Coefficient 95% CI p Value
Health utility
EQ-5D-5L score 0.9 0.8 −0.072 −0.103 to −0.041 0.001 −0.052 −0.082 to −0.022 0.001‡ −0.040 −0.071 to −0.008 0.013
Health-related quality of life
QLQ-C30: global
health status
72.5 74.1 1.549 −1.367 to 4.466 0.298 3.318 0.400 to 6.237 0.026 4.063 1.024 to 7.101 0.009
QLQ-C30: physical
functioning
85.9 80.6 −5.297 −8.480 to −2.114 0.001‡ −3.357 −6.361 to −0.352 0.029 −2.029 −5.103 to 1.046 0.196
QLQ-C30: role
functioning
85.7 77.3 −8.359 −12.335 to −4.384 0.0001‡ −6.781 −10.742 to −2.821 0.001‡ −5.218 −9.263 to −1.174 0.011
QLQ-C30: emotional
functioning
84.8 82.0 −2.770 −5.682 to 0.141 0.062 −0.887 −3.745 to 1.970 0.543 0.097 −2.797 to 2.991 0.948
QLQ-C30: cognitive
functioning
83.9 81.3 −2.578 −5.278 to 0.122 0.061 −0.782 −3.515 to 1.952 0.575 −0.503 −3.316 to 2.311 0.726
QLQ-C30: social
functioning
86.1 81.1 −5.004 −8.488 to −1.520 0.005 −3.283 −6.803 to 0.237 0.068 −2.437 −6.097 to 1.222 0.192
QLQ-C30: fatigue 19.9 27.2 7.299 4.178 to 10.421 0.0001‡ 5.167 2.068 to 8.266 0.001‡ 3.893 0.703 to 7.082 0.017
QLQ-C30: nausea
and vomiting
3.1 3.8 0.717 −0.545 to 1.979 0.265 −0.115 −1.437 to 1.207 0.865 −0.732 −2.268 to 0.805 0.350
QLQ-C30: pain 11.1 19.4 8.264 4.882 to 11.645 0.0001‡ 6.399 3.053 to 9.745 0.0001‡ 5.829 2.349 to 9.308 0.001‡
QLQ-C30: dyspnoea 12.2 19.9 7.711 3.962 to 11.461 0.0001‡ 6.125 2.382 to 9.869 0.001‡ 5.336 1.376 to 9.296 0.008
QLQ-C30: insomnia 21.0 28.3 7.272 3.230 to 11.315 0.0001‡ 4.995 1.018 to 8.972 0.014 3.588 −0.565 to 7.741 0.090
QLQ-C30: appetite
loss
5.2 7.1 1.848 −0.580 to 4.276 0.136 0.451 −1.999 to 2.900 0.718 0.347 −2.241 to 2.934 0.793
QLQ-C30:
constipation
11.5 11.4 −0.155 −3.243 to 2.934 0.922 −1.868 −4.976 to 1.240 0.239 −1.731 −4.907 to 1.445 0.285
QLQ-C30: diarrhoea 8.8 8.2 −0.624 −2.938 to 1.690 0.597 −1.585 −3.973 to 0.803 0.193 −1.954 −4.579 to 0.671 0.144
QLQ-C30: financial
difficulties
10.2 9.8 −0.392 −2.958 2.174 0.765 −1.454 −4.091 to 1.182 0.279 −1.713 −4.460 1.034 0.221
Psychological well-being
DASS: distress 4.9 6.4 1.559 0.403 to 2.715 0.008 1.062 −0.095 to 2.219 0.072 0.652 −0.529 to 1.834 0.279
DASS: anxiety 3.2 4.5 1.285 0.375 to 2.195 0.006 0.893 −0.010 to 1.797 0.053 0.828 −0.070 to 1.725 0.071
DASS: depression 4.0 4.9 0.957 −0.089 to 2.002 0.073 0.620 −0.417 to 1.657 0.241 0.402 −0.688 to 1.492 0.469
Results are weighted by country, age at diagnosis and time since diagnosis with RoI as baseline.
Higher symptom scores indicate more/worse symptoms or where appropriate better functioning or quality of life.
*Linear regression model adjusted for current age, number of comorbidities, time since diagnosis and method of diagnosis.
†Linear regression model adjusted for above plus prostatectomy, external beam radiotherapy, brachytherapy and hormone therapy.
‡Significant difference between countries.
DASS, Depression, Anxiety and Stress Scale; NI, Northern Ireland; RoI, Republic of Ireland.
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The PCa-speciﬁc symptom reported as most distressing
to men is urinary incontinence.18 19 In this study,
current urinary incontinence was reported by 15% of
men who had been diagnosed with early disease and
20% of those with late disease, irrespective of jurisdic-
tion and thus intensity of investigation. Erectile dysfunc-
tion is reported as a long-term irreversible side effect of
treatment,20 especially following prostatectomy.21 The
levels of erectile dysfunction—56% in early disease and
67% in late disease—were the same in responders from
NI and RoI and are similar to those reported in other
population-based surveys.22 In patients with early
disease, only bowel problems, a recognised side effect of
radiotherapy,22 23 remained signiﬁcantly higher in NI
than in RoI, after adjustment for patient characteristics
and treatments. Patients with cancers at other sites,
including the colon and rectum, receive radiotherapy to
the bowel area; however, colorectal cancer incidence
rates and use of radiotherapy as treatment for this
cancer are higher in RoI than in NI.24 Physical symp-
toms associated with ADT—breast changes, hot ﬂashes
and libido loss—were reported with a similar frequency
by men from NI and RoI with early disease but were sig-
niﬁcantly more common in patients with late disease
from NI compared with those from RoI. The almost
twofold higher levels of ever ADT reported by men from
NI compared with men from RoI were taken into
account in the multivariate analysis. We did not,
however, have data on the duration, type or dose of ADT
used which might have affected the patient-reported out-
comes. We further note that no between-country
difference was found when the subgroup of men cur-
rently on ADT were analysed separately (data not
shown).
Outcomes related to HRQoL, including functioning,
general cancer symptoms, health utility and psycho-
logical well-being, showed only minimal variations
between survivors from RoI and NI; in multivariate ana-
lyses, pain was reported as higher in NI in patients with
early disease; however, using internationally recognised
scales, the observed difference in scores (between 19.4
and 11.1) would be considered only minimally clinically
signiﬁcant.25 Pelvic pain is an acknowledged side effect
of radiation treatment22 and this was reported more
often by men from NI. This greater usage of radiation in
NI, however, was accounted for in the multivariate ana-
lysis. The ﬁnding might be explained by higher levels of
disease progression or poorer control of pain in NI. We
did not collect information on recurrence or use of pain
control and hence could not explore this further. The
signiﬁcantly higher level of ﬁnancial difﬁculties identi-
ﬁed by men from RoI is possibly a reﬂection of cancer-
related out-of-pocket costs borne by patients in
RoI. Previous work in RoI, which included PCa survivors,
found that cancer-related ﬁnancial stress and strain is
common,26 and this may be, in part, a function of the
complex mixed public–private healthcare system in
operation. Other studies have shown associations
between ﬁnancial burden and psychological well-being
and HRQoL among patients with cancer/cancer
survivors.27This may in part explain the lower, although
not signiﬁcant, GHSs reported by men in RoI compared
Table 4 Prostate cancer-related physical symptoms—late disease patients
Stage III/IV—any Gleason Univariate model Multivariate model 1* Multivariate model 2†
Weighted proportion
OR OR OR
Ongoing side
effect
(NI vs RoI) (NI vs RoI) (NI vs RoI)
RoI (%) NI (%) (RoI as baseline) (RoI as baseline) (RoI as baseline)
Urinary incontinence 22.2 15.9 0.65 0.66 0.88
(0.44 to 0.97) p=0.035 (0.44 to 0.99) p=0.047 (0.55 to 1.41) p=0.591
Loss of libido 51.6‡ 64.7‡ 1.68‡ 1.61‡ 1.32
(1.22 to 2.31) p=0.001 (1.16 to 2.23) p=0.005 (0.92 to 1.90) p=0.129
Erectile dysfunction 66.9 66.4 0.95 1.09 1.29
(0.68 to 1.33) p=0.784 (0.77 to 1.55) p=0.623 (0.87 to 1.89) p=0.202
Bowel problems 14.2 21.7 1.60 1.40 1.19
(1.07 to 2.39) p=0.021 (0.90 to 2.16) p=0.133 (0.75 to 1.87) p=0.458
Breast changes
(gynaecomastia)
9.4‡ 23.3‡ 2.80‡ 3.09‡ 2.30‡
(1.81 to 4.32) p<0.001 (1.94 to 4.91) p<0.001 (1.41 to 3.73) p=0.001
Hot flashes 18.8‡ 41.1‡ 2.95‡ 2.79‡ 2.33‡
(2.08 to 4.18) p<0.001 (1.95 to 3.99) p<0.001 (1.55 to 3.51) p<0.001
Fatigue 24.6‡ 39.0‡ 1.93‡ 1.71‡ 1.53
(1.39 to 2.70) p<0.001 (1.20 to 2.44) p=0.003 (1.05 to 2.23) p=0.028
Results are weighted by country, age at diagnosis and time since diagnosis.
*Logistic regression model adjusted for current age, number of comorbidities, time since diagnosis and method of diagnosis.
†Logistic regression model adjusted for above plus prostatectomy, external beam radiotherapy, brachytherapy and hormone therapy records
with missing treatment or method of diagnosis dropped from all models (n=12). Significant difference at p<0.05 but with Bonferroni correction
applied.
‡Significant difference between countries with RoI as baseline.
NI, Northern Ireland; RoI, Republic of Ireland.
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Table 5 Patient-reported health utility, health-related quality of life and psychological well-being outcomes late stage prostate cancer—RoI versus NI
Weighted
mean
Univariate model Multivariate model 1* Multivariate model 2†
NI vs RoI (ie, RoI is baseline) NI vs RoI (ie, RoI is baseline) NI vs RoI (ie, RoI is baseline)
Outcome scale RoI NI Coefficient 95% CI p Value Coefficient 95% CI p Value Coefficient 95% CI p Value
Health utilities
EQ-5D-5L score 0.8 0.7 −0.061 0.102 to 0.020 0.004 −0.030 0.071 to 0.011 0.151 −0.027 0.071 to 0.017 0.233
Health-related quality of life
C30: global health status 67.8 71.2 3.405 −0.374 to 7.183 0.077 5.996 2.310 to 9.681 0.001‡ 5.472 1.525 to 9.420 0.007
QLC-C30: physical
functioning
78.6 75.2 −3.432 −7.457 to 0.594 0.095 0.476 −3.450 to 4.402 0.812 1.174 −3.174 to 5.522 0.596
QLC-C30: role
functioning
75.7 72.2 −3.520 −8.653 to 1.613 0.179 0.140 −5.055 to 5.335 0.958 1.355 −4.423 to 7.134 0.645
QLC-C30: emotional
functioning
81.0 82.1 1.091 −2.532 to 4.715 0.554 3.014 −0.614 to 6.643 0.103 3.750 −0.280 to 7.781 0.068
QLC-C30: cognitive
functioning
79.9 79.3 −0.538 −4.367 to 3.291 0.783 1.754 −1.990 to 5.498 0.358 1.818 −2.300 to 5.937 0.386
QLC-C30: social
functioning
76.4 76.6 0.231 −4.245 to 4.707 0.919 2.581 −1.991 to 7.154 0.268 2.915 −2.081 to 7.911 0.252
QLC-C30: fatigue 27.1 31.6 4.542 0.322 to 8.762 0.035 0.838 −3.352 to 5.028 0.695 −0.607 −5.189 to 3.976 0.795
QLC-C30: nausea and
vomiting
6.2 5.3 −0.844 −3.227 to 1.540 0.487 −1.762 −4.426 to 0.903 0.195 −1.949 −4.800 to 0.902 0.180
QLC-C30: pain 17.5 23.8 6.325 1.986 to 10.664 0.004 3.689 −0.715 to 8.094 0.101 2.638 −2.218 to 7.494 0.287
QLC-C30: dyspnoea 20.3 22.9 2.611 −2.213 to 7.434 0.288 −1.720 −6.391 to 2.951 0.470 −3.083 −8.216 to 2.050 0.239
QLC-C30: insomnia 26.2 26.7 0.518 −4.594 to 5.629 0.842 −2.442 −7.522 to 2.638 0.346 −3.823 −9.618 to 1.972 0.196
QLC-C30: appetite loss 8.4 9.8 1.335 −1.990 to 4.661 0.431 −0.716 −4.357 to 2.926 0.700 −1.686 −5.641 to 2.268 0.403
QLC-C30: constipation 14.4 14.3 −0.069 −4.036 to 3.898 0.973 −2.397 −6.641 to 1.847 0.268 −2.738 −7.258 to 1.783 0.235
QLC-C30: diarrhoea 11.4 12.2 0.793 −2.844 to 4.430 0.669 −0.566 −4.298 to 3.165 0.766 −1.182 −5.181 to 2.817 0.562
QLC-C30: financial
difficulties
17.9 10.4 −7.454 −11.176 to −3.731 0.0001‡ −8.137 −11.772 to −4.503 0.0001‡ −8.629 −12.770 to −4.488 0.0001‡
Psychological well-being
DASS: stress 5.7 6.3 0.644 −0.805 to 2.093 0.383 0.360 −1.062 to 1.781 0.620 0.743 −0.816 to 2.301 0.350
DASS: anxiety 3.9 4.4 0.477 −0.641 to 1.596 0.402 −0.151 −1.292 to 0.991 0.796 −0.086 −1.342 to 1.170 0.893
DASS: depression 5.1 5.7 0.581 −0.871 to 2.033 0.432 0.080 −1.366 to 1.526 0.914 0.172 −1.431 to 1.775 0.833
Results are weighted by country, age at diagnosis and time since diagnosis.
Higher symptom scores indicate more/worse symptoms or, where appropriate, better functioning or quality of life.
*Logistic regression model adjusted for current age, number of comorbidities, time since diagnosis and method of diagnosis.
†Logistic regression model adjusted for age, number of comorbidities, time since diagnosis, method of diagnosis, treatment type—prostatectomy, external beam radiotherapy, brachytherapy and
androgen deprivation therapy.
‡Significant difference between countries.
NI, Northern Ireland; RoI, Republic of Ireland.
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with men from NI (although no differences were
detected in DASS-21 outcomes).
Comparisons between countries with different policies
and practices concerning PCa detection can make a
valuable contribution to the debate on use of PSA to
test for PCa. We have shown that patient-reported out-
comes are very similar in RoI and NI despite different
levels of PSA testing and diagnosed PCa. However, it is
important to set these ﬁndings in the context of the
wider population. It has been estimated that between
1994 and 2005, compared with the 1994 disease levels,
there were 5938 ‘extra’ cases of PCa diagnosed in RoI
and 763 in NI.4 Since 2005, the numbers of PCas in the
two jurisdictions have continued to rise. As we have
shown here and elsewhere, physical side effects, such as
erectile dysfunction and incontinence, are common
among prostate cancer survivors in Ireland,21 echoing
studies in other settings.20 These side effects can be
viewed, in part, as a consequence of widespread PSA
testing since, in the absence of testing, many of the men
with side effects may never have been detected with PCa
or, if they had been detected, this may have been at an
older age, so they would have had to live less time with
side effects. The burden of side effects, in terms of the
numbers (and rates) of men in the population living
with these, is greater in RoI than in NI (ie, higher in the
population with higher levels of PSA testing). This
important population-level health impact of more inten-
sive PSA testing—and the little (at best) impact of PSA
testing on mortality4—needs to be considered alongside
the ﬁndings from the current analysis.
CONCLUSION
Following 20 years of higher levels of PCa detection in
RoI than NI, when stage at presentation is taken into
account, health outcomes among PCa survivors differed
little between countries. However, the increased intensity
of investigation has resulted in a population impact with
many additional men in RoI having ongoing PCa-related
physical symptoms, a risk for all areas with higher levels
of testing.
Based on this evidence, the use of PSA to test high
numbers of asymptomatic men as occurred in RoI has
not reduced mortality compared with NI but has left
many more men with side effects. We recommended
that men be offered a PSA test only after informed dis-
cussion as recommended by current guidelines.
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